Updates

Date: June 30, 2026 BSE Limited, National Stock Exchange of India Limited 20th Floor, P.J. Towers, Exchange Plaza, C-1, Block G, Dalal Street, Bandra Kurla Complex, Bandra (E), Mumbai - 400001. Mumbai – 400 051 BSE Scrip Code: 544449 NSE Scrip Symbol: ANTHEM Subject: Business Responsibility and Sustainability Report (BRSR) for the FY 2025-26 Dear Sir/Madam Pursuant to Regulation 34 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/CFD-SEC-2/P/CIR/2023/122 dated July 12, 2023, the requirement to include a Business Responsibility and Sustainability Report (BRSR) in the Annual Report shall become applicable to the Company from FY 2026-27. However, the Company has voluntarily undertaken the BRSR reporting exercise for FY 2025-26 in line with its commitment to responsible business practices, sustainability and enhanced stakeholder disclosures. In this regard, in compliance with Regulation 34(2)(f) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are hereby enclosing the Business Responsibility and Sustainability Report (“BRSR”) for FY 2025–26, along with the Independent Assurance Statement, which forms part of the Annual Report for FY 2025–26. The above intimation is made available on the Company’s website at https://www.anthembio.com/investors/ We request you to kindly take the same on record. Thanking you, Yours truly, For Anthem Biosciences Limited Divya Prasad Company Secretary & Compliance Officer Membership No: A41438 CORPORATE OVERVIEW STATUTORY REPORTS FINANCIAL STATEMENTS NOTICE Business Responsibility & Sustainability Report SECTION A: GENERAL DISCLOSURES I. Details of listed entity 1. Corporate Identity Number (CIN) of the Company L24233KA2006PLC039703 2. Name of the Company Anthem Biosciences Limited 3. Year of Incorporation 2006 4. Registered Office Address No. 49, F1 & F2, Canara Bank Road, Bommasandra Industrial Area, 5. Corporate Address Phase 1, Bommasandra, Bangalore, Karnataka, India, 560 099. 6. Email Address Investors.abl@anthembio.com 7. Telephone +91 080 6672 4000 8. Website https://anthembio.com/ 9. Financial Year Reported FY 2025 - 2026 10. Name of the Stock Exchanges where shares are listed BSE Limited (“BSE”) and National Stock Exchange of India Limited (“NSE”) 11. Paid-up Capital (in Rs. Mn) Rs. 1123.43 12. Name and contact details (telephone, email address) of the Divya Prasad person who may be contacted in case of any queries on the (Company Secretary and Compliance officer) BRSR report Email: investors.abl@anthembio.com Telephone: +91 080 6672 4000 13. Reporting boundary - Are the disclosures under this report The disclosures presented in this BRSR are on a consolidated basis made on a standalone basis (i.e. only for the entity) or on a unless otherwise stated. consolidated basis (i.e. for the entity and all the entities which form a part of its consolidated financial statements, taken together). 14. Name of assessment or assurance provider Vinay and Keshava LLP 15. Type of assessment or assurance obtained Limited Assurance on BRSR Core indicators II. Products/Services 16. Details of business activities (accounting for 90% of the turnover) Description of Main Activity Description of Business Activity % of turnover of the Company 1. Contract research, development and manufacturing services Provide scientific solutions 100% through integrated research, development and manufacturing 17. Products/Services sold by the Company (accounting for 90% of the turnover) Product/Service NIC Code % of total turnover contributed 1. Contract Research , Development and Manufacturing services 72 (Scientific Research and 100% Development) III. Operations 18. Number of locations where plants and/or operations/offices of the Company are situated: Location Number of plants Number of offices Total National 3 0 3 International 0 0 0 Anthem Biosciences Limited Annual Report 2025-26 19. Markets served by the Company a. Number of locations Locations Number National (No. of States) 25 International (No. of Countries) 50 b. What is the contribution of exports as a percentage of the total turnover of the Company? Exports contribute to 85% of the revenue from operations for FY 2026. c. Types of customers The Company's customer base comprises mid-sized and large biotechnology companies, as well as virtual biotechnology companies. These customers primarily engage with the Company for contract research, development, and manufacturing services across the pharmaceutical and biotechnology sectors. The customer profile includes organizations seeking end-to-end support in drug discovery, development, and commercialization, reflecting a diverse, innovation-driven, and globally oriented client ecosystem. IV. Employees (on a Consolidated Basis) 20. Details as at the end of Financial Year a. Employees and workers (including differently abled): Sl. Male Female Particulars Total (A) No. No (B) % (B/A) No (C) % (C/A) EMPLOYEES 1. Permanent (D) 2,282 1,909 83.65% 373 16.35% 2. Other than Permanent (E) 0 0 0 0 0 3. Total employees (D + E) 2,282 1,909 83.65% 373 16.35% WORKERS 4. Permanent (F) 0 0 0 0 0% 5. Other than Permanent (G) 1,020 945 92.65% 75 7.35% 6. Total workers (F + G) 1,020 945 92.65% 75 7.35% b. Differently abled Employees and workers: Sl. Male Female Particulars Total (A) No. No (B) % (B/A) No (C) % (C/A) EMPLOYEES 1. Permanent (D) 2 1 50% 1 50% 2. Other than Permanent (E) 0 0 0% 0% 0% 3. Total employees (D + E) 2 1 50% 1 50% WORKERS 4. Permanent (F) - - - - - 5. Other than Permanent (G) - - - - - 6. Total workers (F + G) - - - - - 21. Participation/Inclusion/Representation of Women No. and percentage of Females Particulars Total (A) No (B) % (B/A) Board of Directors* 8 1 12.50% Key Management Personnel** 5 1 20% *The Company has three Executive Directors and four Independent Directors. **The disclosure includes three Executive Directors designated as Key Managerial Personnel (KMPs). 22. Turnover rate for permanent employees and workers (disclose trends for the past 3 years) FY’2025-26 FY’2024-25 FY’2023-24 Particulars Male Female Total Male Female Total Male Female Total Permanent Employees 8.88% 1.98% 10.86% 9.47% 2.57% 12.04% 13.46% 3.60% 17.06% Permanent Workers NA NA NA NA NA NA NA NA NA CORPORATE OVERVIEW STATUTORY REPORTS FINANCIAL STATEMENTS NOTICE V. Holding, Subsidiary and Associate Companies (including joint ventures) 23. Name of holding/subsidiary/associate companies/joint ventures Indicate whether Holding/ Does the entity indicated at column A, Sl. Name of the holding/ subsidiary/ % of shares held Subsidiary/Associate/Joint participate in the Business Responsibility No. associate companies/joint ventures (A) by the Company Venture initiatives of the Company (Yes/No) 1 Neoanthem Lifesciences Private Ltd. Wholly Owned Subsidiary 100% Yes VI. CSR Details 24. (i) Whether CSR is applicable as per section 135 of Companies Act, 2013: Yes (ii) Turnover (in Rs. Mn): 20,893.12 (iii) Net worth (in Rs. Mn): 30,768.08 Note: As per Ind AS standalone financial statements VII. Transparency and Disclosure Compliances 25. Complaints/Grievances on any of the principles (Principle 1 to 9) under the National Guidelines on Responsible Business Conduct: Grievance Redressal FY’2025-26 FY’2024-25 Stakeholder Mechanism in place No. of group from whom (Yes/No) (If yes, then No. of complaints No. of No. of complaints complaints complaints compliant is provide web link for pending resolution Remarks pending resolution at Remarks filed during filed during received grievance redressal at close of the year close of the year the year the year policy)* Communities Yes 0 0 - 0 0 - Investors (other than Yes 0 0 0 0 shareholders) Shareholders Yes 0 0 0 0 Employees and workers Yes 0 0 0 0 Customers Yes 0 0 0 0 Value Chain Partners Yes 0 0 0 0 *The Company's policies for redressing stakeholder grievances are available on its website at https://anthembio.com/. In addition, rel [Showing first 8,000 characters — download PDF for full document]